How do you design randomised trials for smaller populations? A framework
Open Access
- 25 November 2016
- journal article
- other
- Published by Springer Nature in BMC Medicine
- Vol. 14 (1) , 1-10
Abstract
How should we approach trial design when we can get some, but not all, of the way to the numbers required for a randomised phase III trial? We present an ordered framework for designing randomised trials to address the problem when the ideal sample size is considered larger than the number of participants that can be recruited in a reasonable time frame. Staying with the frequentist approach that is well accepted and understood in large trials, we propose a framework that includes small alterations to the design parameters. These aim to increase the numbers achievable and also potentially reduce the sample size target. The first step should always be to attempt to extend collaborations, consider broadening eligibility criteria and increase the accrual time or follow-up time. The second set of ordered considerations are the choice of research arm, outcome measures, power and target effect. If the revised design is still not feasible, in the third step we propose moving from two- to one-sided significance tests, changing the type I error rate, using covariate information at the design stage, re-randomising patients and borrowing external information. We discuss the benefits of some of these possible changes and warn against others. We illustrate, with a worked example based on the Euramos-1 trial, the application of this framework in designing a trial that is feasible, while still providing a good evidence base to evaluate a research treatment. This framework would allow appropriate evaluation of treatments when large-scale phase III trials are not possible, but where the need for high-quality randomised data is as pressing as it is for common diseases.Keywords
Funding Information
- Medical Research Council (MC_EX_G0800814)
- Medical Research Council (MC_EX_G0800814)
- Medical Research Council (MC_EX_G0800814)
This publication has 25 references indexed in Scilit:
- The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studiesTrials, 2014
- Variance reduction in randomised trials by inverse probability weighting using the propensity scoreStatistics in Medicine, 2013
- Trial unpredictability yields predictable therapy gainsNature, 2013
- Assessing potential sources of clustering in individually randomised trialsBMC Medical Research Methodology, 2013
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- Handling Covariates in the Design of Clinical TrialsStatistical Science, 2008
- Why Most Published Research Findings Are FalsePLOS Medicine, 2005
- Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancerStatistics in Medicine, 2003
- Statistical Issues in Drug DevelopmentTechnometrics, 1999
- Bayesian Approaches to Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 1994